Search

Displaying results 891 - 900 of 1237 in total
  1. Target

    Sodium/glucose cotransporter 2

    go.drugbank.com/bio_entities/BE0004753
    TargetTransporterHumans

    Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose at the plasma membrane, with a Na(+) to sugar coupling ratio of 1:1 (PubMed:20980548, PubMed:28592437, PubMed:34880493, PubMed:37217492, PubMed:38057552). Tran...

    Synonyms: Low affinity sodium-glucose cotransporter
  2. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells.

  3. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64068] NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other

  4. Drug

    Allantoin

    go.drugbank.com/drugs/DB11100
    ApprovedInvestigational

    Allantoin is a substance that is endogenous to the human body and also found as a normal component of human diets [FDA Label]. In healthy human volunteers, the mean plasma concentration of allantoin is about 2-3 mg/l. During exercise, th...

    Mixtures: Bye Bye Burn Lot, eos THE FIXER HEAL REPAIR MEDICATED ANALGESIC LIP
  5. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 202...

  6. Drug

    Dibromothymoquinone

    go.drugbank.com/drugs/DB04646
    Experimental

    At low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors, probably acting as a plastoquinone antagonist.

  7. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  8. Drug

    Alethine

    go.drugbank.com/drugs/DB05800
    Investigational

    It is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models.

  9. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA gr...

  10. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to t...